| Biomarker ID | 1811 |
| PMID | 30926382 |
| Year | 2019 |
| Biomarker | PHI (Prostate Health Index) |
| Biomarker Basis | Concentration Based |
| Biomolecule | Protein |
| Source | Serum |
| Subjects | Humans |
| Regulation | NA |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | NA |
| Experiment | Prostate Cancer Vs No Prostate Cancer |
| Type of Biomarker | Diagnostic |
| Cohort | 221 patients were included in the study. 129 were non cancerous and 82 were cancerous. 121 patients underwent nonfused biopsy and 90 had fused biopsies |
| Senstivity | NA |
| Specificity | NA |
| AUC | Non Fused Biopsy: Univariate: 0.78 (95% CI: 0.67-0.88); Multivariate: 0.79 (95% CI: 0.68-0.89)Fused Biopsy: Univariate: 0.70 (95% CI: 0.59-0.81); |
| Accuracy | NA |
| Level Of Significance | NA |
| Method Used | NA |
| Clinical | No |
| Remarks | PHI: [-2]proPSA/fPSA x√PSA. Base Model includes: age, DRE, and prior biopsy |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | NA |